Capricor Therapeutics Hits 52-Week Low at $5.43 Amid Financial Struggles

Capricor Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 5.43 on November 10, 2025. This decline marks a significant downturn for the stock, which has seen a substantial drop of 68.54% over the past year, contrasting sharply with the S&P 500's performance of 12.65% during the same period.
The company's financial metrics reveal ongoing challenges, with net sales for the first nine months reported at USD 11.13 million, reflecting a decline of 46.91%. Additionally, Capricor's operating cash flow has reached a low of USD -52.99 million, indicating financial strain. The rising cost of raw materials, which increased by 101.11% year-over-year, further complicates the company's financial landscape.

With a market capitalization of USD 290 million, Capricor Therapeutics continues to face hurdles, including a negative return on equity of -66.66% and a price-to-book ratio of 2.77. The stock's performance has consistently lagged behind broader market indices, highlighting the need for strategic reassessment within the company.